Please use this identifier to cite or link to this item: https://doi.org/10.1371/journal.pone.0173279
Title: Validation of a commercially available test that enables the quantification of the numbers of CGG trinucleotide repeat expansion in FMR1 gene
Authors: Lim G.X.Y.
Yeo M.
Koh Y.Y.
Winarni T.I.
Rajan-Babu I.-S.
Chong S.S. 
Faradz S.M.H.
Guan M.
Keywords: allele
consensus
genotype
human
major clinical study
mutation
polymerase chain reaction
quantitative study
reproducibility
trinucleotide repeat
validation process
female
fragile X syndrome
genetics
male
trinucleotide repeat
validation study
DNA
FMR1 protein, human
fragile X mental retardation protein
DNA
Female
Fragile X Mental Retardation Protein
Fragile X Syndrome
Genotype
Humans
Male
Mutation
Polymerase Chain Reaction
Trinucleotide Repeat Expansion
Issue Date: 2017
Publisher: Public Library of Science
Citation: Lim G.X.Y., Yeo M., Koh Y.Y., Winarni T.I., Rajan-Babu I.-S., Chong S.S., Faradz S.M.H., Guan M. (2017). Validation of a commercially available test that enables the quantification of the numbers of CGG trinucleotide repeat expansion in FMR1 gene. PLoS ONE 12 (3) : e0173279. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0173279
Abstract: In the present study, we evaluated a commercially available TP-PCR-based assay, the FastFraX™ FMR1 Sizing kit, as a test in quantifying the number of CGG repeats in the FMR1 gene. Based on testing with well characterized DNA samples from Coriell, the kit yielded size results within 3 repeats of those obtained by common consensus (n = 14), with the exception of one allele. Furthermore, based on data obtained using all Coriell samples with or without common consensus (n = 29), the Sizing kit was 97.5% in agreement with existing approaches. Additionally, the kit generated consistent size information in repeatability and reproducibility studies (CV 0.39% to 3.42%). Clinical performance was established with 198 archived clinical samples, yielding results of 100% sensitivity (95% CI, 91.03% to 100%) and 100% specificity (95% CI, 97.64% to 100%) in categorizing patient samples into the respective normal, intermediate, premutation and full mutation genotypes. © 2017 Lim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Source Title: PLoS ONE
URI: https://scholarbank.nus.edu.sg/handle/10635/166016
ISSN: 19326203
DOI: 10.1371/journal.pone.0173279
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1371_journal_pone_0173279.pdf1.06 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.